Clinical Trial Update: AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19 [NA]

View source ↗

Summary

A terminated clinical trial update for AirFLO2 treatment in patients with COVID-19‑related hypoxia and tachypnea; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoxia
• Respiratory Distress or Tachypnea Associated with COVID-19

Drugs mentioned

• AirFLO2

Snippet

Sponsor: Duke University | Conditions: Corona Virus Infection, Respiratory Rate | NA | Status: TERMINATED | Results posted: 2022-11-25